Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with procedures ...

A new study reveals that only about 1 in 3 patients with prostate cancer have a successful first CT simulation, while 1 in 6 need to be rescheduled for another day.

Today, a patient diagnosed with advanced prostate cancer has options. Doctors can offer a suite of androgen-suppressing drugs to extend his life. There are genetic tests that can show whether he’s a ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...